BIOMAT Database Logo BIOMAT Database Logo

The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. 1998

M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Department of Chemical & Physical Sciences, DuPont Merck Pharmaceutical Company, Wilmington, DE 19880-0500, USA.

Cyclic urea SD146, a potent HIV protease inhibitor bearing a flat resistance profile, possessed poor solubility and bioavailability, which precluded further development of the compound. In an effort to improve upon the pharmacokinetic profile of the compound, several analogs modified at the P1/P1' residues were prepared and evaluated. Several of those compounds displayed significant improvement of physical properties.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III

Related Publications

M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
April 1998, Bioorganic & medicinal chemistry letters,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
November 1999, Bioorganic & medicinal chemistry letters,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Environmentally benign synthesis of unsymmetrical ureas and their evaluation as potential HIV-1 protease inhibitors via a computational approach.
April 2024, Molecular diversity,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
January 1994, Science (New York, N.Y.),
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Synthesis and stacked conformations of symmetrical and unsymmetrical oligo-ureas of metaphenylenediamine.
March 2007, The Journal of organic chemistry,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
August 1996, Journal of medicinal chemistry,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
June 1998, Journal of medicinal chemistry,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
October 1994, Biopharmaceutics & drug disposition,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
August 1999, Bioorganic & medicinal chemistry letters,
M Patel, and R F Kaltenbach, and D A Nugiel, and R J McHugh, and P K Jadhav, and L T Bacheler, and B C Cordova, and R M Klabe, and S Erickson-Viitanen, and S Garber, and C Reid, and S P Seitz
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
June 2000, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!